If your gastroenterologist has prescribed Tremfya for Crohn's disease and you have UnitedHealthcare, you are asking a question that has very little plain-language guidance behind it. Tremfya, known generically as guselkumab, only received its Crohn's approval in 2025, so most of what you can find online is a manufacturer page or a dense policy PDF. The short answer is that UnitedHealthcare can cover Tremfya for Crohn's disease, but coverage is not automatic. It runs through prior authorization, usually requires you to have tried other treatments first, and depends on the specifics of your individual plan. This article maps how UnitedHealthcare handles a newly approved biologic and what you can do to clear those requirements.
What Tremfya Is Approved to Treat
Tremfya is an interleukin-23 antagonist that binds the p19 subunit of IL-23, a protein that drives inflammation in Crohn's disease. The U.S. Food and Drug Administration approved Tremfya for adults with moderately to severely active Crohn's disease on March 20, 2025. This was its fourth approved use, after plaque psoriasis, psoriatic arthritis, and ulcerative colitis. The approval was supported by the GALAXI and GRAVITI phase 3 trials, in which more patients on guselkumab reached clinical remission at week 12 than on placebo. Because this indication is so recent, Tremfya tends to sit later in the treatment sequence rather than as a first choice. The label allows either intravenous or subcutaneous induction, followed by subcutaneous maintenance dosing.
How UnitedHealthcare Manages Tremfya
UnitedHealthcare runs its pharmacy benefit through OptumRx, and specialty drugs like Tremfya are dispensed through specialty pharmacy channels rather than a regular retail counter. Tremfya is subject to prior authorization, which means your prescriber has to submit clinical documentation and get approval before the plan will pay. UnitedHealthcare publishes a prior authorization and medical necessity policy for Tremfya that lists separate criteria for each approved condition, including Crohn's disease. When the criteria are met, that same policy states an authorization is typically issued for 12 months before a reauthorization review. The exact tier, copay, and benefit details are not the same for every member, so the published policy describes the clinical bar, not a guarantee that your plan will pay any specific amount.
The Step Therapy Gate for Crohn's
This is where most denials happen. UnitedHealthcare's policy requires that, before Tremfya, you have a documented diagnosis of moderately to severely active Crohn's disease plus one of two histories. The first option is failure of a conventional therapy at up to maximally indicated doses, and the second is prior treatment with another targeted biologic approved for Crohn's. That biologic list in the policy names agents such as adalimumab, certolizumab, vedolizumab, mirikizumab, upadacitinib, risankizumab, and ustekinumab. Treatment guidelines push in the same direction. The American Gastroenterological Association recommends early use of biologics, with anti-TNF agents or ustekinumab as first-line options, which is why a preferred anti-TNF is often expected ahead of a newer agent like Tremfya. The policy also requires that Tremfya be prescribed by or with a gastroenterologist.
How to Check Your Own Plan
Published policies describe the general rules, but your specific plan documents control what actually happens at the pharmacy. Start by pulling your plan's formulary and your member coverage documents, both of which UnitedHealthcare members can access through the member portal or by calling the number on the back of the insurance card. Look for whether Tremfya appears on the formulary, what step therapy or prior authorization notes are attached, and which specialty pharmacy is required.
Three things are worth confirming directly:
Whether Tremfya is covered and on which formulary tier for your plan
What prior treatments your plan's documentation says you must have tried first
Which specialty pharmacy will fill the prescription
Asking these before your prescriber submits the request can prevent a denial that comes purely from a missing record rather than a real coverage gap.
Building the Medical Necessity Case
Because Tremfya is usually a later-line agent for Crohn's, the strength of the prior authorization depends on documentation of what came before it. The reviewer is checking your history against the policy criteria, so your prescriber's submission should clearly list each prior conventional therapy or biologic, including the drug name, the dates, the duration, and the reason it was stopped, whether that was lack of response, loss of response, or a side effect. Vague statements that a patient "failed prior therapy" are easy to deny, while a dated, specific record maps cleanly onto the criteria UnitedHealthcare actually uses. Keeping your own running list of every Crohn's medication you have tried, and what happened on each, gives your gastroenterology team the raw material to assemble a request that matches the step therapy gate on the first try.
Appealing a Denial
If UnitedHealthcare denies the request, the denial is not the end. The written notice explains the reason, and that reason tells you what to fix. Many step-therapy denials are overturned once the missing documentation of prior drugs is supplied. UnitedHealthcare describes several routes in its appeals and reconsideration process, including a peer-to-peer review where your prescriber speaks directly with a plan medical director, a pre-service appeal before the medication is dispensed, and formal reconsideration and appeal steps. Deadlines and exact procedures vary by plan type, so the specific timelines in your denial letter and member documents are the ones that govern your case. If a preferred drug genuinely is not appropriate for you, your prescriber can also request a formal exception explaining why the required step is medically contraindicated. Tracking each submission and its decision date keeps an appeal moving.
The Bottom Line
UnitedHealthcare can cover Tremfya for Crohn's disease, but as a recently approved IL-23 inhibitor it is generally positioned after conventional therapy and a preferred biologic in the plan's step therapy logic. Coverage flows through OptumRx prior authorization, runs on documentation of your prior treatments, and ultimately depends on your individual plan's formulary and benefit design rather than a blanket rule. The most useful thing you can do is verify your own plan's requirements early, keep a precise record of every Crohn's medication you have tried and why it was stopped, and treat a first denial as a fixable step rather than a final answer.
This article is for educational purposes and is not medical advice. It is researched against current AGA clinical guidelines and peer-reviewed sources. Always discuss treatment decisions with your care team.